Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.
Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.
All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.
Regeneron Pharmaceuticals reported a 31% decline in Q4 2022 revenues, totaling $3.41 billion, and a 24% decrease for the full year 2022, at $12.17 billion. Excluding REGEN-COV and Ronapreve, Q4 revenues rose 14%. Notable product performance included EYLEA U.S. net sales dropping 3% but increasing 8% for the year, while Dupixent showed strong growth with a 38% quarterly rise. The company allocated $3.4 billion for business development and share repurchases in 2022. A new $3.0 billion share repurchase program was approved in January 2023. Meanwhile, the FDA accepted a BLA for aflibercept 8 mg aimed at treating wet AMD.
Regeneron Pharmaceuticals and Sanofi announce that Dupixent has received European Commission approval for the treatment of eosinophilic esophagitis (EoE) in patients aged 12 and older. Dupixent is now the first targeted medicine available for this chronic inflammatory disease in the EU. In pivotal trials, 60% of patients treated with Dupixent experienced histological remission, significantly improving their swallowing abilities. The treatment shows potential in addressing other conditions related to type 2 inflammation. The safety profile remained consistent, with common side effects including injection site reactions and infections.
Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Dupixent® (dupilumab), recommending its approval to treat severe atopic dermatitis in children aged 6 months to 5 years. This decision is based on a successful Phase 3 trial showing Dupixent significantly improved skin clearance and reduced disease severity. Currently, about 80,000 children in Europe could benefit from this treatment. The final decision from the European Commission is pending.
On January 24, 2023, Regeneron Pharmaceuticals (NASDAQ: REGN) and Society for Science announced the finalists of the Regeneron Science Talent Search 2023, recognizing 40 high school seniors for their innovative scientific research. This prestigious competition, celebrating its 82nd year, awards over $1.8 million in prizes, with top awards reaching $250,000. The finalists, chosen from over 1,900 applicants, represent diverse scientific disciplines and address pressing societal issues such as climate change, public health, and social justice. The competition includes a rigorous judging process and culminates in an awards ceremony on March 14, 2023.
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the date for its fourth quarter and full year 2022 financial results. The report will be released on February 3, 2023, prior to the U.S. market opening. A conference call and webcast to discuss the results will take place at 8:30 AM Eastern Time on the same day. Participants can join via the company's website or register for phone access. Regeneron focuses on developing innovative medicines, with a strong pipeline aimed at various serious diseases.
Regeneron Pharmaceuticals (NASDAQ: REGN) received marketing and manufacturing authorization from Japan's Ministry of Health for Libtayo® (cemiplimab), marking it as the first approved monotherapy for advanced cervical cancer in the country. This approval follows positive results from the Phase 3 EMPOWER-Cervical 1 trial, which showed significant survival benefits compared to chemotherapy. The global incidence of cervical cancer is rising, with about 600,000 new cases and 350,000 deaths each year. Libtayo was previously approved in the EU for similar indications.
Regeneron Pharmaceuticals and Sanofi announced that a Phase 3 trial of Dupixent (dupilumab) 300 mg weekly for treating eosinophilic esophagitis (EoE) showed significant improvements in patient histology and symptoms compared to placebo. Improvements were sustained for up to one year in patients aged 12 and older. Dupixent is the first U.S. approved targeted treatment for EoE. The FDA approved Dupixent in May 2022, and the EMA has given a positive opinion for its use in Europe. Safety results matched Dupixent's known profile, suggesting a favorable risk-benefit ratio.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:00 a.m. Pacific Time. Investors can access the presentation via the company's website, with an archived version available for 30 days thereafter. Regeneron, a leading biotechnology firm founded by physician-scientists, develops innovative medicines for serious diseases across various therapeutic areas including eye diseases, cancer, and rare conditions.
Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee has recommended Dupixent for approval to treat adolescents and adults aged 12 and over with eosinophilic esophagitis (EoE). This would make Dupixent the first targeted treatment for EoE in the EU, following its U.S. approval in May 2022. The positive recommendation is based on pivotal trial data showing significant improvements in patients' ability to swallow and histological remission. The European Commission will make a final decision soon.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
